Association of neuropeptide Y gene rs16147 polymorphism with metabolic syndrome in patients with documented coronary artery disease

Parizadeh, Seyed Alireza; Jamialahmadi, Khadijeh; Rooki, Hassan; Zaim-Kohan, Houshang; Mirhafez, Seyed Reza; Hosseini, Nedasadat; Mohiti-Ardakani, Javad; Moohebati, Mohsen; Masoudi-Kazemabad, Ali; Ferns, Gordon A.; Ghayour‐Mobarhan, Majid

doi:10.3109/03014460.2014.916750

Cited by 16 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some works [27] have shown a relationship of rs16147 with different cardiovascular risk factors, for example an increased risk of metabolic syndrome and its related phenotypes, such as central obesity and hyperglycemia, in obese subjects without the A allele. Another study [8] reported this relationship with metabolic syndrome in a non-Caucasian population. Insulin resistance is the main alteration in metabolic syndrome.…”

Section: Discussionmentioning

confidence: 89%

“…In addition, the above-mentioned SNP has been shown to be related with serum levels of NPY [5] and to be responsible for more than half of the variation in the expression of NPY [6]. Few previous studies have shown an association between SNPs of NPY and early onset of atherosclerosis, stroke, and hypertension [7,8]. Moreover, adipose tissue is recognized as an endocrine organ producing several proteins, called adipokines, produced by adipose tissue (leptin, adiponectin, resistin, etc.).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Polymorphism rs16147 of the Neuropeptide Y Gene Modifies the Response of Cardiovascular Risk Biomarkers and Adipokines to Two Hypocaloric Diets

Luis

Izaola²,

Primo³

et al. 2017

Lifestyle Genomics

View full text Add to dashboard Cite

Aims: Our aim was to evaluate the relationship of weight loss and changes in adipokine levels after two hypocaloric diets in obese subjects with polymorphism rs16147 of the neuropeptide Y gene. Subjects and Methods: A population of 283 obese patients was analyzed. At the basal visit, patients were randomly allocated to one of two diets for a period of 3 months (diet I, low in carbohydrates; diet II, low in fat). Results: With diet I and in both genotype groups (major versus minor allele), body mass index (BMI), weight, fat mass, waist circumference, and leptin decreased. With diet II and in all genotypes, BMI, weight, fat mass, waist circumference, and leptin decreased. With both diets and in subjects with the minor allele, insulin levels (diet I: major allele -1.7 ± 7.8 IU/L versus minor allele -4.2 ± 6.1 IU/L, p = 0.01; diet II: major allele -2.3 ± 6.1 IU/L versus minor allele -4.0 ± 5.2 IU/L, p = 0.02) and insulin resistance (diet I: major allele -0.2 ± 3.1 units versus minor allele -1.7 ± 3.0 units, p = 0.03; diet II: major allele -0.9 ± 2.0 units versus minor allele -1.7 ± 1.3 units, p = 0.01) decreased. Conclusion: The rs16147 genotype affected the reduction in insulin resistance and insulin levels in response to two different hypocaloric diets in obese subjects, with a lack of response in subjects with the major allele.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Polymorphism rs16147 of the Neuropeptide Y Gene Modifies the Response of Cardiovascular Risk Biomarkers and Adipokines to Two Hypocaloric Diets

Luis

Izaola²,

Primo³

et al. 2017

Lifestyle Genomics

View full text Add to dashboard Cite

show abstract

“…Moreover, the results in the literature are contradictory. Parizadeh et al [9] observed that GG homozygotes of rs14167 had a significantly decreased risk of MetS when compared with A allele carriers. The difference in design between this study and ours is important: firstly, the population of the previous study was not Caucasian and, secondly, all patients [9] had a severe complication of MetS as an inclusion criterion (i.e., documented coronary artery disease).…”

Section: Discussionmentioning

confidence: 99%

“…The association between NPY rs16147 SNP and MetS has not been studied extensively, and only 1 study in an Iranian population has been performed [9]. Given the limited information about the relationship of this SNP with MetS and adipokines in a Caucasian population, this study was designed with the aim to investigate the relationship of NPY rs16147 with body weight, insulin resistance, serum adipokine levels, and presence of MetS.…”

Section: Introductionmentioning

confidence: 99%

Association of Neuropeptide Y Gene rs16147 Polymorphism with Cardiovascular Risk Factors, Adipokines, and Metabolic Syndrome in Patients with Obesity

Luis

Izaola²,

Fuente³

et al. 2016

Lifestyle Genomics

View full text Add to dashboard Cite

Background and Aims: The NPY gene has 4 exons, and it is located at 7p15.1. The main genetic variant described in this gene is rs16147. The aim of this study was to investigate the relationship of NPY rs16147 with body weight, insulin resistance, serum adipokine levels, and risk of metabolic syndrome (MetS). Methods: A population of 1,005 obese patients was analyzed in a cross-sectional survey. Weight, fat mass, waist circumference, blood pressure, basal glucose, C-reactive protein, insulin, insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR]), lipid profile, and adipocytokine (leptin, adiponectin, and resistin) levels were measured. The genotype of the NPY gene polymorphism (rs16147) was studied. Results: Body mass index (1.0 ± 0.1; p < 0.05), weight (2.8 ± 0.4 kg; p < 0.05), fat mass (1.8 ± 0.3 kg; p < 0.05), waist circumference (1.9 ± 0.2 cm; p < 0.05), leptin level (15.4 ± 8.2 ng/mL; p < 0.05), insulin level (5.1 ± 1.3 mIU/L; p < 0.05), and HOMA-IR (1.4 ± 0.1 units; p < 0.05) were lower in A allele carriers than in non-A allele carriers in males. Males with an A allele had a lower percentage of MetS (54.8 vs. 69.1%; p < 0.05), central obesity (94.5 vs. 100%; p < 0.05), and hyperglycemia (24.7 vs. 33.8%; p < 0.05) than non-A allele carriers. Logistic regression analysis indicated that male non-A allele carriers had an increased risk of MetS (odds ratio [OR] = 1.26, 95% confidence interval [CI] = 1.17-1.83; p = 0.034), an increased risk of central obesity (OR = 1.08, 95% CI = 1.02-1.11; p = 0.044), and an increased risk of hyperglycemia (OR = 1.20, 95% CI = 1.09-1.79; p = 0.028) after adjusting for age. Conclusions: In obese males, the rs164147 polymorphism of the NPY gene is associated with leptin, insulin level, HOMA-IR, and an increased risk of MetS and its related phenotypes, such as central obesity and hyperglycemia.

show abstract

“…Although, in our previous study, we have reported that the NPY rs16147 polymorphism may be associated with the presence of the metabolic syndrome among patients with documented CAD, and patients carrying the A allele are associated with a higher prevalence of the metabolic syndrome [28], the association between the NPY rs16147 SNP and CAD has not been extensively studied, and, to our knowledge, there is little information about the genetic susceptibility to CAD in the Iranian population. This cross-sectional study was designed to evaluate the potential association between the NPY rs16147 polymorphism and the risk of CAD in an Iranian population.…”

Section: Introductionmentioning

confidence: 99%

Lack of an Association between a Functional Polymorphism in the Neuropeptide Y Gene Promoter and the Presence of Coronary Artery Disease in an Iranian Population

Parizadeh

Jamialahmadi²,

Rooki³

et al. 2014

Ann Nutr Metab

Self Cite

View full text Add to dashboard Cite

Background/Aims: Several genetic factors have been identified that may contribute to the risk of coronary artery disease (CAD). Variants of the neuropeptide Y (NPY) gene, whose products play an important role in regulating several physiological functions, have been associated with the risk of CAD in some populations. The purpose of this study was to investigate the relationship between the NPY gene rs16147 polymorphism and the presence of CAD in an Iranian population. Methods: DNA samples of 922 subjects, including 433 with angiographically defined CAD (CAD+), 196 without angiographically defined significant CAD (CAD-) and 293 controls, were genotyped using polymerase chain reaction based on the amplification-refractory mutation system. Logistic regression analyses were performed to assess the association of rs16147 genotypes with the presence of significant CAD. Results: Although logistic regression analysis indicated that the NPY polymorphism rs16147 was nominally associated with an increased risk of CAD (p < 0.05), after adjustment for confounding factors, there was no evidence for any signiﬁcantly increased or decreased risk of CAD with this polymorphism. However, in stratiﬁed analyses, the C allele was signiﬁcantly associated with a reduced risk of CAD in males and subjects who were <50 years of age. Conclusions: This study suggests that the rs16147 polymorphism in the NPY gene may not be a potential contributor to the risk of CAD in an Iranian population.

show abstract

Association of neuropeptide Y gene rs16147 polymorphism with metabolic syndrome in patients with documented coronary artery disease

Abstract: The rs16147 polymorphism may be associated with presence of MetS among subjects with documented CAD. Carriage of NPY A allele in patients with CAD is associated with a higher prevalence of MetS.

Cited by 16 publications

References 33 publications

Polymorphism <b><i>rs16147</i></b> of the <b><i>Neuropeptide Y</i></b> Gene Modifies the Response of Cardiovascular Risk Biomarkers and Adipokines to Two Hypocaloric Diets

Polymorphism <b><i>rs16147</i></b> of the <b><i>Neuropeptide Y</i></b> Gene Modifies the Response of Cardiovascular Risk Biomarkers and Adipokines to Two Hypocaloric Diets

Association of Neuropeptide Y Gene rs16147 Polymorphism with Cardiovascular Risk Factors, Adipokines, and Metabolic Syndrome in Patients with Obesity

Lack of an Association between a Functional Polymorphism in the Neuropeptide Y Gene Promoter and the Presence of Coronary Artery Disease in an Iranian Population

Contact Info

Product

Resources

About